Strata Critical Medical (SRTA) Cash from Investing Activities (2019 - 2026)

Strata Critical Medical (SRTA) has reported Cash from Investing Activities for 7 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 21.18% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $74.1 million (up 1532.45% YoY), while the FY2025 annual figure was $69.8 million, up 6965.16% from the prior year.
• Cash from Investing Activities grew to $24.7 million in Q1 2026 per SRTA's latest filing, from $18.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $207.6 million in Q2 2022 and bottomed at -$16.9 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged $21.9 million across 5 years, with a median of $11.0 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 20849.06% — and 2024, when it sank 548.01%.
• Strata Critical Medical's Cash from Investing Activities stood at $207.6 million in 2022, then plunged by 99.96% to $75000.0 in 2023, then jumped by 5201.33% to $4.0 million in 2024, then soared by 359.38% to $18.3 million in 2025, then soared by 35.39% to $24.7 million in 2026.
• Business Quant data shows SRTA's Cash from Investing Activities at $24.7 million in Q1 2026, $18.3 million in Q4 2025, and $2.4 million in Q3 2025.